SPONSOR

The First Affiliated Hospital with Nanjing Medical University

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 1

Conditions studied: Locally Advanced Pancreatic Cancer With KRAS G12D Mutation Gastric Cancer Gastric Cancer Metastatic to Regional Lymph Nodes Intrahepatic Cholangiocarcinoma (Icc)Neoadjuvant Therapy Esophageal Squamous Cell Carcinoma Fertility Issues Blastocyst IVF Embryo Culture Large B-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical University is a clinical research sponsor with 18 registered studies on ClinicalTrials.gov, of which 18 are actively recruiting participants. Research covers conditions including Locally Advanced Pancreatic Cancer With KRAS G12D Mutation, Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes, Intrahepatic Cholangiocarcinoma (Icc).

The trial portfolio spans Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — The First Affiliated Hospital with Nanjing Medical University

How many clinical trials has The First Affiliated Hospital with Nanjing Medical University sponsored?

ClinicalMetric currently tracks 18 clinical trials sponsored by The First Affiliated Hospital with Nanjing Medical University, of which 18 are actively recruiting participants. These trials cover conditions including Locally Advanced Pancreatic Cancer With KRAS G12D Mutation, Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does The First Affiliated Hospital with Nanjing Medical University research focus on?

The First Affiliated Hospital with Nanjing Medical University clinical trials span Locally Advanced Pancreatic Cancer With KRAS G12D Mutation, Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes, Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a The First Affiliated Hospital with Nanjing Medical University clinical trial?

To participate in a The First Affiliated Hospital with Nanjing Medical University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital with Nanjing Medical University trials with current recruitment status updated daily.

The First Affiliated Hospital with Nanjing Medical University

Frequently Asked Questions — The First Affiliated Hospital with Nanjing Medical University

Clinical Trials by The First Affiliated Hospital with Nanjing Medical University

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

Omission of SLNB in CN0 Early Breast Cancer

Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC

To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Interventional Treatment of Chronic Tinnitus With Acoustic Stimulation

Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease